Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 
Volume 63, Issue 1, Pages (July 2015)
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Volume 46, Issue 3, Pages (March 2007)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus  Takasuke Fukuhara, Chikako Ono, Francesc Puig-Basagoiti, Yoshiharu.
Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
NS5A inhibitors in the treatment of hepatitis C
HCV NS5A Inhibitors: The Devil Is in the Details
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Volume 5, Issue 6, Pages (June 2009)
Immigration and viral hepatitis
Figure 1 HCV life cycle and site of action of DAAs
Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert 
Volume 138, Issue 1, Pages 6-12.e2 (January 2010)
Hepatitis C virus entry and glucocorticosteroids
The Influenza Virus Enigma
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer 
HCV and the hepatic lipid pathway as a potential treatment target
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Volume 68, Issue 3, Pages (March 2018)
A dive into the complexity of type I interferon antiviral functions
RNAi – A powerful tool to unravel hepatitis C virus–host interactions within the infectious life cycle  Joachim Lupberger, Laurent Brino, Thomas F. Baumert 
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Volume 45, Issue 4, Pages (October 2006)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Advancing hepatitis B virus entry inhibitors
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
EASL Clinical Practice Guidelines: Wilson’s disease
HCMV jogs the ‘memory’ of NK cells in HBV
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Breaking the Barrier: Host Cell Invasion by Lujo Virus
Protein interactions during the flavivirus life cycle elucidated by MS-based proteomics. Protein interactions during the flavivirus life cycle elucidated.
The role of quantitative hepatitis B surface antigen revisited
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Development of Effective Vaccines against Pandemic Influenza
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Michael S. Diamond, Theodore C. Pierson  Cell 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Anti−Hepatitis C Virus Drugs in Development
Simplified overview of the HCV life cycle and sites of direct acting antiviral therapies. Simplified overview of the HCV life cycle and sites of direct.
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
The hantavirus life cycle.
Woo-Yong Lee, Paul Kubes  Journal of Hepatology 
Presentation transcript:

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies  Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert  Journal of Hepatology  Volume 54, Issue 3, Pages 566-576 (March 2011) DOI: 10.1016/j.jhep.2010.10.014 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. A model of HCV life cycle, with potential targets for virus neutralizing antibodies and other entry inhibitors, is shown. HCV is believed to first interact with HS and LDLR on the basolateral membrane surface of hepatocytes to allow concentration of the virion. Subsequently, interaction with other host factors such as SR-BI, CD81, CLDN1, and OCLN ultimately leads to viral internalization via clathrin-mediated endocytosis. For CLDN1 both junctional and non-junctional forms have been described (for review see [141]). Fusion between viral and endosomal membranes is followed by release of the viral genome into the cytosol where translation and replication take place. HCV particles are then assembled and released from the host cell. An alternative route of viral entry is direct cell–cell transmission which is resistant to neutralizing antibodies. Entry inhibitors can potentially interfere with the viral life cycle at different steps, i.e. viral binding, post-binding and fusion. Ab, antibody; apo, apolipoprotein; BC, bile canaliculi; CLDN1, claudin 1; HCV, hepatitis C virus; HS, heparan sulfate; JAM, junction-associated adhesion molecule; LDLR, low-density lipoprotein receptor; nAb, neutralizing antibody; OCLN, occludin; PS-ON, phosphorothioate oligonucleotides; SR-BI, scavenger receptor class B type I; ZO, zona occludens. Journal of Hepatology 2011 54, 566-576DOI: (10.1016/j.jhep.2010.10.014) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2011 54, 566-576DOI: (10. 1016/j. jhep. 2010. 10 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2011 54, 566-576DOI: (10. 1016/j. jhep. 2010. 10 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions